ISARIC

ISARIC

The International Severe Acute Respiratory and Emerging Infection Consortium was established to coordinate clinical research responses to emerging infectious disease outbreaks. It links clinical networks, academic institutions, public health agencies, and philanthropic organizations to accelerate evidence generation during epidemics and pandemics. ISARIC collaborates with hospitals, universities, research councils, and international bodies to harmonize protocols, share data, and support standardized clinical characterization.

History

ISARIC grew from discussions among clinicians at World Health Organization meetings, drawing expertise from investigators involved in Severe Acute Respiratory Syndrome and Ebola virus epidemic in West Africa clinical responses. Early contributors included researchers affiliated with University of Oxford, Imperial College London, London School of Hygiene & Tropical Medicine, and Centers for Disease Control and Prevention networks. The consortium formalized during preparatory efforts for pandemic influenza exercises influenced by lessons from the 2009 H1N1 pandemic and modeled after cooperative frameworks like Global Outbreak Alert and Response Network and Coalition for Epidemic Preparedness Innovations. ISARIC’s formative period intersected with initiatives led by Wellcome Trust, Bill & Melinda Gates Foundation, and regional public health authorities such as European Centre for Disease Prevention and Control.

Organization and Governance

ISARIC operates as a global federation incorporating academic hospitals, national research institutes, and coordinating centers in regions similar to structures seen at National Institutes of Health, Public Health England, and Institut Pasteur. Governance draws on advisory boards with representation from experts comparable to those at Centers for Disease Control and Prevention, World Bank, and major university health systems like Johns Hopkins University and Harvard Medical School. Strategic oversight incorporates ethics input akin to Nuffield Council on Bioethics and legal frameworks that echo agreements used by European Commission consortia and Gavi, the Vaccine Alliance. Executive management interacts with networks such as Global Research Collaboration for Infectious Disease Preparedness and reporting aligns with standards used by ClinicalTrials.gov and regional regulatory authorities like European Medicines Agency.

Research Activities and Protocols

ISARIC develops standardized case report forms and clinical characterization protocols used in settings from tertiary centers associated with Mayo Clinic to field hospitals deployed in crises similar to MSF (Doctors Without Borders) operations. Protocols reflect methodologies applied in trials at Oxford Vaccine Group and observational cohorts led by entities like Karolinska Institutet and University of Cape Town. These tools enable harmonized collection comparable to datasets curated by Imperial College London modelling teams and registries maintained by European Respiratory Society. Protocols are designed to integrate with trial platforms such as RECOVERY Trial and adapt to pathogen-specific studies exemplified by responses to Middle East respiratory syndrome coronavirus and Zika virus outbreak research.

Data Sharing and Collaboration

ISARIC emphasizes rapid data sharing through platforms analogous to repositories operated by Global Health Data Exchange and collaborative networks like Open Data Institute. Data governance models reflect principles advanced by WHO R&D Blueprint and data-sharing agreements similar to those negotiated by the Human Genome Project. Collaboration spans partners such as African CDC, Pan American Health Organization, and academic consortia at University of São Paulo and Peking University. The consortium coordinates with trial consortia like Solidarity Trial and integrates clinical metadata with genomic surveillance efforts run by groups such as Nextstrain and sequencing centers at Wellcome Sanger Institute.

Major Contributions and Impact

ISARIC contributed standardized tools that accelerated characterization of diseases during the COVID-19 pandemic, informing treatment guidelines used by bodies like World Health Organization and national agencies including Public Health England and CDC (United States). Its datasets supported analyses published alongside research from University of Oxford and Imperial College London modelers, and informed clinical management strategies similar to recommendations from Surviving Sepsis Campaign. ISARIC-enabled harmonization facilitated multinational observational studies involving hospitals affiliated with Addenbrooke's Hospital, Groote Schuur Hospital, and Singapore General Hospital, influencing vaccine and therapeutic prioritization discussions with stakeholders such as Gavi, the Vaccine Alliance and CEPI.

Funding and Partnerships

Funding streams mirror arrangements seen with major supporters like Wellcome Trust, Bill & Melinda Gates Foundation, and national research funders such as UK Research and Innovation and National Institutes of Health. Strategic partnerships include collaborations with academic centers including University of Oxford, Imperial College London, and University of Melbourne, healthcare organizations like NHS England, and international agencies comparable to World Health Organization and United Nations programmes. ISARIC’s resource mobilization strategies align with philanthropic consortia models used by Welcome Trust, Rockefeller Foundation, and multilateral initiatives like Global Fund.

Criticisms and Challenges

Critiques of ISARIC-style consortia parallel concerns raised about other global research networks such as equity of data access noted in debates involving Human Genome Project and capacity disparities highlighted by collaborations between institutions like Harvard Medical School and lower-resource partners. Challenges include harmonizing ethical review processes across jurisdictions represented by bodies like European Commission and African Union, negotiating intellectual property arrangements reminiscent of disputes in HIV/AIDS research, and ensuring sustainable funding beyond emergency cycles like those following the 2014–2016 Ebola outbreak. Operational hurdles reflect issues faced by multinational studies like SOLIDARITY Trial and data integration problems encountered in cross-border surveillance initiatives coordinated by WHO.

Category:Medical research organizations